Delia Chaverri Rada

Delia Chaverri Rada

Neurologist

After completing her neurology training at Hospital Ramon y Cajal in Madrid, Dr Delia Chaverri entered as staff Neurologist at the Hospital Carlos III. There she combined her duty as general neurologist with a special involvement with ALS patients. With Dr J. Mora, she established the first ALS Unit in Spain. Devoted mainly to patient care, she has participated in a large number of ALS international clinical trials. In 2014, the Hospital Carlos III merged with Hospital La Paz, forming a single institution where she has been coordinating the ALS unit since 2016. More than 300 patients are treated regularly at the unit by a high level multidisciplinary team.

Connect
Connect trials
Recruiting
Phase iii

PHOENIX trial

Industry trial

Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.

Read more
Recruiting
Phase iii

ADORE Trial

Industry trial

Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).

Read more
Recruiting
Phase iii

COURAGE-ALS Trial

Industry trial

In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.

Read more
Active
Phase ii

APL2-ALS-206 Trial

Industry trial

In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.

Read more
Active
Phase ii

RT001 in Amyotrophic Lateral Sclerosis

Industry trial

In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.

Read more
Recruiting
Phase iii

TUDCA-ALS

Investigator initiated trial

This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.

Read more